Silence Therapeutics (SLN) Enterprise Value (2018 - 2026)
Silence Therapeutics (SLN) posted Enterprise Value of -$134.5 million for Q1 2026, down 58.05% sequentially from -$85.1 million in Q4 2025, and up 35.37% YoY from -$99.4 million in Q1 2025.
Silence Therapeutics (SLN) Enterprise Value (2018 - 2026) Analysis & Trends
Silence Therapeutics has reported Enterprise Value for 9 years, with the latest figure at -$134.5 million in Q1 2026.
- Quarterly Enterprise Value rose 35.37% year-over-year to -$134.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$134.5 million (up 35.37% YoY) and the FY2025 annual result came in at -$85.1 million, up 54.26% from the prior year.
- Enterprise Value declined to -$134.5 million in Q1 2026 per SLN's latest filing, from -$85.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$64.3 million in Q4 2022 and troughed at -$208.1 million in Q1 2025.
- A 5-year average of -$122.7 million and a median of -$118.3 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value slumped 177.47% in 2024, then surged 54.26% in 2025.
- Over 5 years, Enterprise Value stood at -$64.3 million in 2022, then decreased by 4.3% to -$67.1 million in 2023, then plunged by 177.47% to -$186.1 million in 2024, then soared by 54.26% to -$85.1 million in 2025, then slumped by 58.05% to -$134.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$134.5 million, -$85.1 million, and -$122.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | -72.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.10 Mn |
| Mar 31, 2026 | -134.52 Mn |
| Dec 31, 2025 | -85.11 Mn |
| Sep 30, 2025 | -122.36 Mn |
| Jun 30, 2025 | -114.16 Mn |
| Mar 31, 2025 | -208.15 Mn |
| Dec 31, 2024 | -186.07 Mn |
| Dec 31, 2023 | -67.06 Mn |
| Dec 31, 2022 | -64.30 Mn |
| Dec 31, 2021 | -99.13 Mn |
| Dec 31, 2020 | -38.22 Mn |
| Dec 31, 2019 | -17.38 Mn |
| Dec 31, 2018 | -27.66 Mn |